ContraVir's Hep B Drug Could Be a Game Changer

Disclosures from NOBLE Life Science Partners, ContraVir, Equity Research, Dec. 19. 2015

The following disclosures relate to relationships between Noble and the company (the "Company") covered by the Noble Research Division and referred to in this research report.

Noble has provided capital markets advisory services in the last 12 months. The Company has attended Noble investor conference(s) in the last 12 months. Noble has arranged non-deal roadshow(s) with investors in the last 12 months.

Noble has received compensation for non-investment banking services in the past 12 months. Noble expects to receive compensation for noninvestment banking services in the next 3 months.

Noble intends to seek compensation for investment banking services and non-investment banking services (securities and non-securities related) within the next 3 months.

Noble is a market maker in the Company.

RESEARCH ANALYST CERTIFICATION

Independence Of View
All views expressed in this report accurately reflect my personal views about the subject securities or issuers.

Receipt of Compensation
No part of my compensation was, is, or will be directly or indirectly related to any specific recommendations or views expressed in the public appearance and/or research report.

Ownership and Material Conflicts of Interest
Neither I nor anybody in my household has a financial interest in the securities of the subject company or any other company mentioned in this report.

Disclosures from Maxim Group, ContraVir Pharmaceuticals Inc., Dec. 19, 2016

I, Gabrielle Zhou, attest that the views expressed in this research report accurately reflect my personal views about the subject security and issuer. Furthermore, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report.

I, Jason Kolbert, attest that the views expressed in this research report accurately reflect my personal views about the subject security and issuer. Furthermore, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report.

The research analyst(s) primarily responsible for the preparation of this research report have received compensation based upon various factors, including the firm’s total revenues, a portion of which is generated by investment banking activities.

Maxim Group makes a market in ContraVir Pharmaceuticals, Inc.

Maxim Group expects to receive or intends to seek compensation for investment banking services from ContraVir Pharmaceuticals, Inc. in the next 3 months.

Disclosures from Laidlaw & Company, ContraVir Pharmaceuticals, Oct. 14, 2016

ANALYST CERTIFICATION
The analyst responsible for the content of this report hereby certifies that the views expressed regarding the company or companies and their securities accurately represent his personal views and that no direct or indirect compensation is to be received by the analyst for any specific recommendation or views contained in this report. Neither the author of this report nor any member of his immediate family or household maintains a position in the securities mentioned in this report.

Laidlaw & Co. has provided any investment banking services for the company (ies) mentioned in this report over the last 12 months, and intends to seek investment banking services for the company (ies) mentioned in this report over the next three months.